Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy QSI?
Source: Newsfilter
- Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
- Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
- Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QSI
Wall Street analysts forecast QSI stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.747
Low
1.50
Averages
2.67
High
4.00
Current: 0.747
Low
1.50
Averages
2.67
High
4.00
About QSI
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
- Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
- Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
See More
Quantum-Si's Proteus Prototype Surpasses Platinum Performance
- Successful Sample Sequencing: Quantum-Si has successfully completed the sequencing of multiple samples on its Proteus prototype system, demonstrating that it exceeds Platinum Pro performance across all relevant metrics, marking a significant milestone in the development of this new platform.
- Significant Technical Advantages: The Proteus prototype system shows substantial improvements in amino acid coverage, read lengths, peptide identification, and sequencing output, even when normalized for the difference in nanowell counts compared to the Platinum Pro chip, highlighting its superior performance.
- Strong Customer Demand: Several customers have expressed interest in providing samples for sequencing on the Proteus prototype, and Quantum-Si is closely collaborating with manufacturing partners to increase the delivery rate of integrated Proteus systems to meet internal R&D demands and offer market sample testing capabilities.
- Optimistic Future Outlook: Quantum-Si expects sequencing performance to continue improving as the Proteus system is further optimized, with plans to provide more updates on this program during the next earnings call, reflecting the company's confidence in future developments.
See More
Quantum-Si Launches Multi-City Roadshow for Proteus Awareness
- Roadshow Launch: Quantum-Si has announced the start of a multi-city roadshow aimed at increasing market awareness of its Proteus platform and protein sequencing applications, with the first event scheduled for April 7, 2026, in Seattle, followed by stops in Washington D.C. and Houston, which is expected to significantly expand its potential customer base.
- Customer Engagement: The roadshow will feature presentations from existing customers showcasing applications of protein sequencing using the company's first-generation Platinum® Pro instrument, which not only helps build customer trust but also creates strong market demand for the upcoming Proteus platform.
- Market Education: Through this roadshow, Quantum-Si aims to accelerate market education and enhance awareness of Proteus, which is expected to exceed the capabilities of Platinum Pro, thereby positioning the company more favorably in the competitive protein analysis market.
- Strategic Importance: CEO Jeff Hawkins stated that this roadshow is a crucial part of the company's pre-launch strategy, designed to rapidly build a funnel of prospective customers through the effectiveness of its direct sales team, laying the groundwork for the commercialization of Proteus.
See More
Analysis of Quantum-Si Inc. Options Trading
- Options Selling Risk: Selling puts does not provide investors with the upside potential of Quantum-Si Inc. shares, as ownership only occurs if the contract is exercised, which requires a 42.8% drop to the $0.50 strike price, highlighting the market risks faced by put sellers.
- Yield Analysis: The only upside for put sellers comes from the premium collected, with an annualized return of 24.6%, which is only meaningful if the stock does not fall below the strike price, reflecting the complexity and potential risks of options trading.
- Volatility Assessment: Quantum-Si Inc. has a trailing twelve-month volatility of 92%, and when combined with fundamental analysis, it can help investors determine whether selling the January 2027 put at the $0.50 strike represents a worthwhile risk-reward scenario, indicating a high-risk, high-reward profile.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components was 1.76 million contracts, with call volume also at 1.76 million, resulting in a put:call ratio of 0.71, indicating a higher-than-normal level of put buyers compared to the long-term median of 0.65, reflecting shifts in market sentiment.
See More
Quantum-Si Projects 2026 as Transition Year with Focus on Proteus Launch
- Revenue Outlook: Quantum-Si anticipates total revenue of approximately $1 million for 2026, primarily driven by consumable utilization, while new capital equipment sales are expected to remain limited, a strategy aimed at laying the groundwork for a strong commercial ramp of Proteus in 2027.
- Proteus Pricing Strategy: The list price for Proteus is set at $425,000, designed to balance its premium value with market accessibility, which is expected to attract a larger number of potential customers and drive future sales growth.
- Customer Expansion Success: The company successfully secured 17 new customers through its instrument placement program, viewed as a key market development tool to build momentum for the Proteus launch, indicating strong market demand potential.
- Financial Performance: Revenue for Q4 2025 was $451,000 with a gross margin of 27%, impacted by a higher proportion of consumable revenue and certain inventory adjustments, yet the overall financial position reflects the company's resilience during the transition year.
See More
Quantum-Si (QSI) Q4 2025 Earnings Call Transcript
See More
Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
- Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
- Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
See More
Quantum-Si's Proteus Prototype Surpasses Platinum Performance
- Successful Sample Sequencing: Quantum-Si has successfully completed the sequencing of multiple samples on its Proteus prototype system, demonstrating that it exceeds Platinum Pro performance across all relevant metrics, marking a significant milestone in the development of this new platform.
- Significant Technical Advantages: The Proteus prototype system shows substantial improvements in amino acid coverage, read lengths, peptide identification, and sequencing output, even when normalized for the difference in nanowell counts compared to the Platinum Pro chip, highlighting its superior performance.
- Strong Customer Demand: Several customers have expressed interest in providing samples for sequencing on the Proteus prototype, and Quantum-Si is closely collaborating with manufacturing partners to increase the delivery rate of integrated Proteus systems to meet internal R&D demands and offer market sample testing capabilities.
- Optimistic Future Outlook: Quantum-Si expects sequencing performance to continue improving as the Proteus system is further optimized, with plans to provide more updates on this program during the next earnings call, reflecting the company's confidence in future developments.
See More
Quantum-Si Launches Multi-City Roadshow for Proteus Awareness
- Roadshow Launch: Quantum-Si has announced the start of a multi-city roadshow aimed at increasing market awareness of its Proteus platform and protein sequencing applications, with the first event scheduled for April 7, 2026, in Seattle, followed by stops in Washington D.C. and Houston, which is expected to significantly expand its potential customer base.
- Customer Engagement: The roadshow will feature presentations from existing customers showcasing applications of protein sequencing using the company's first-generation Platinum® Pro instrument, which not only helps build customer trust but also creates strong market demand for the upcoming Proteus platform.
- Market Education: Through this roadshow, Quantum-Si aims to accelerate market education and enhance awareness of Proteus, which is expected to exceed the capabilities of Platinum Pro, thereby positioning the company more favorably in the competitive protein analysis market.
- Strategic Importance: CEO Jeff Hawkins stated that this roadshow is a crucial part of the company's pre-launch strategy, designed to rapidly build a funnel of prospective customers through the effectiveness of its direct sales team, laying the groundwork for the commercialization of Proteus.
See More
Analysis of Quantum-Si Inc. Options Trading
- Options Selling Risk: Selling puts does not provide investors with the upside potential of Quantum-Si Inc. shares, as ownership only occurs if the contract is exercised, which requires a 42.8% drop to the $0.50 strike price, highlighting the market risks faced by put sellers.
- Yield Analysis: The only upside for put sellers comes from the premium collected, with an annualized return of 24.6%, which is only meaningful if the stock does not fall below the strike price, reflecting the complexity and potential risks of options trading.
- Volatility Assessment: Quantum-Si Inc. has a trailing twelve-month volatility of 92%, and when combined with fundamental analysis, it can help investors determine whether selling the January 2027 put at the $0.50 strike represents a worthwhile risk-reward scenario, indicating a high-risk, high-reward profile.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components was 1.76 million contracts, with call volume also at 1.76 million, resulting in a put:call ratio of 0.71, indicating a higher-than-normal level of put buyers compared to the long-term median of 0.65, reflecting shifts in market sentiment.
See More
Quantum-Si Projects 2026 as Transition Year with Focus on Proteus Launch
- Revenue Outlook: Quantum-Si anticipates total revenue of approximately $1 million for 2026, primarily driven by consumable utilization, while new capital equipment sales are expected to remain limited, a strategy aimed at laying the groundwork for a strong commercial ramp of Proteus in 2027.
- Proteus Pricing Strategy: The list price for Proteus is set at $425,000, designed to balance its premium value with market accessibility, which is expected to attract a larger number of potential customers and drive future sales growth.
- Customer Expansion Success: The company successfully secured 17 new customers through its instrument placement program, viewed as a key market development tool to build momentum for the Proteus launch, indicating strong market demand potential.
- Financial Performance: Revenue for Q4 2025 was $451,000 with a gross margin of 27%, impacted by a higher proportion of consumable revenue and certain inventory adjustments, yet the overall financial position reflects the company's resilience during the transition year.
See More
Quantum-Si (QSI) Q4 2025 Earnings Call Transcript
See More
